Skip to main content
ICCC
NASDAQ Life Sciences

ImmuCell Q3 Net Income $953K as Sales Jump 46%; Cash Nearly Doubles to $7.9M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$10.22
Mkt Cap
$92.82M
52W Low
$4.52
52W High
$12.1
52W Position info
126% above low
Off High info
16% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

ICCC has more than doubled off its 52-week low of $4.52.

Summary

ImmuCell's Q3 10-Q confirms the pre-announced 46% sales growth and $953K net income, and shows cash nearly doubling to $7.9 million with a new $3.0 million credit line in the works.


Key Events · Earnings and Guidance · ICCC

  • Q3 Sales Up 46% to $8.0M

    Product sales rose to $8,039,951 from $5,506,122, driven by higher First Defense volumes and price increases; gross profit climbed 50.4% to $3,555,060.

  • Net Income $953K vs Year-Ago Loss

    Q3 net income was $952,510 ($0.10 per diluted share) versus a $(139,748) loss; nine-month net income of $4,728,773 includes a $2.0 million one-time settlement.

  • Cash Nearly Doubles to $7.9M

    Cash and equivalents reached $7,914,406 at September 30, 2026, up from $3,806,831 at December 31, 2025; operating cash flow was $7,348,008 for the nine months.

  • New $3.0M Credit Line Negotiated

    ImmuCell negotiated a new $3,000,000 line of credit with Maine Community Bank, expected to sign in Q4 2026; the prior $1,000,000 facility expired September 11, 2026.


Analysis · ICCC · Life Sciences

The headline numbers were already out, but the 10-Q fills in what matters: cash and equivalents nearly doubled to $7.9 million from $3.8 million at year-end, helped by a $2.0 million settlement with a former contract manufacturer. Nine-month net income of $4.7 million includes that one-time settlement, so the underlying run-rate is thinner than the headline. The company also negotiated a new $3.0 million line of credit to replace the $1.0 million facility that expired September 11, 2026, and says it has funding for at least the next 12 months. Against that, the First Defense capacity expansion still needs another $6.3 million over nine to 15 months, and two distributors account for 71% of sales and 82% of receivables — a concentration that cuts both ways if either pulls back.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ICCC was trading at $10.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $92.8M. The 52-week trading range was $4.52 to $12.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ICCC - Latest Insights

ICCC
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $10.22
Real-time Price: $10.75 info
Change: +$0.530 (+5%) info
Market Cap: $97.732M info
ICCC
Oct 12, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $10.00
Real-time Price: $10.75 info
Change: +$0.750 (+8%) info
Market Cap: $97.732M info
ICCC
Aug 13, 2026, 4:14 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $10.90
Real-time Price: $10.75 info
Change: -$0.150 (-1%) info
Market Cap: $97.732M info
ICCC
Aug 13, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $10.90
Real-time Price: $10.75 info
Change: -$0.150 (-1%) info
Market Cap: $97.732M info
ICCC
Jul 09, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $11.46
Real-time Price: $10.75 info
Change: -$0.705 (-6%) info
Market Cap: $97.732M info